Forecast
The analysts' average price target is €2.28 (+216.67%). The median is €2.28 (+216.67%).
| Buy |
Â
4 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Organogenesis misses Q2 forecasts significantly, stock falls after-hours
Organogenesis reported an adjusted loss of $0.77 per share for Q2 on revenue of $42.8 million, materially missing consensus estimates; the stock plunged 18.67% in after-hours trading to $1.96. Revenue fell 58% year‑over‑year due to CMS reimbursement changes but rose 18% sequentially and wound care sales volume increased 30%. The company cut its 2026 revenue guidance to $179–215 million, delayed the Dermagraft launch by about one year, and announced restructurings expected to save more than $32 million. Management expects sequential recovery in the second half of the year and positive adjusted EBITDA in Q4 2026, but sees ongoing near-term pressure from reimbursement risks. » More on de.investing.com
Organogenesis closes ATM distribution agreement for up to $75 million
Organogenesis has entered an at‑the‑market distribution agreement with BTIG and Citizens JMP for the potential issuance of up to $75 million of common stock. The financing option comes as the shares trade at $2.39, down about 54% year‑to‑date. The company reported weaker Q1 results (EPS -$0.44, revenue $37.2 million) and received FDA acceptance of the ReNu filing with a decision goal of April 24, 2027. Analysts cut valuations and cited reimbursement and market‑structure risks in the advanced wound care segment. » More on de.investing.com
Organogenesis misses Q1 forecasts by a wide margin and lowers full-year outlook
Organogenesis reported Q1 2026 EPS of -$0.44 (expected -$0.29) and revenue of $37.2m (expected $43.3m). Net product revenue fell 58% year over year. The company cut its full-year revenue guidance to $270–310m (a decline of 45–52%) and plans cost reductions equal to 25% of 2026 operating expenses. Management highlights progress on the BLA filing for ReNu and expects sequential revenue growth in H2, but continues to see pressure from regulatory and reimbursement challenges. » More on de.investing.com
Organogenesis stock rises 20% after positive study result for PuraPly AM
Organogenesis reports that PuraPly AM met the primary endpoint in a randomized, controlled trial of 170 patients and showed a statistically significantly higher wound closure rate for diabetic foot ulcers versus standard care at 12 weeks. PuraPly AM combines a cross-linked collagen matrix with the antimicrobial agent polyhexamethylene biguanide. The company expects the data will strengthen the product's inclusion in future reimbursement guidelines and its role in the healing paradigm. » More on de.investing.com
Organogenesis plans phased BLA submission for ReNu by year-end
Organogenesis announced, after a successful type-B meeting with the FDA, that it intends to submit a Biologics License Application (BLA) for ReNu on a phased basis before the end of December. The FDA confirmed that the clinical development program — two randomized, controlled phase 3 trials, a commercial track record and the RMAT designation — is appropriate for a BLA submission. ReNu is a cryopreserved allogeneic amnion transplant for the treatment of symptomatic knee osteoarthritis; the stock is trading near its 52-week low and has fallen about 57% year-to-date. » More on de.investing.com
Financials
In the last quarter, ORGANOGENESIS HLDGS had revenue of €40.13m and net profit of -€26.16m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 40.13m | 68.70% |
| Gross profit | 20.8m | 78.63% |
| Net profit | -26.16m | 242.33% |
| EBITDA | -22.25m | 192.76% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €93.23m |
Number of shares | 129.8m |
52-week high/low | €5.38 - €0.66 |
| Dividends | No |
Beta | 1.27 |
P/E ratio | -0.67 |
PEG ratio | 0.00 |
P/B ratio | 0.85 |
P/S ratio | 0.29 |
Company profile
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
| Name | ORGANOGENESIS HLDGS |
| CEO | Gary S. Gillheeney |
| Headquarters | Canton,
ma USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/01/2017 |
| Employees | 854 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ORGO |
Frankfurt | 2PQ.F |
DĂĽsseldorf | 2PQ.DU |
MĂĽnchen | 2PQ.MU |